Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 18 of 18 entries
View as:

AK105 Plus Anlotinib Hydrochloride Combined With Albumin Paclitaxel as a First-line Therapy in Patients With Advanced Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05244993 Org: User:
Start: 07/31/22 End: 03/31/24 Due: 03/31/25

Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases

Phase: N/A Priority: Normal
NCT ID: NCT05774964 Org: User:
Start: 03/15/23 End: 03/15/25 Due: 03/15/26

Clinical Study of Chidamide Combined With Fulvestrant in the Treatment of Hormone Receptor-positive Advanced Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05047848 Org: User:
Start: 08/18/21 End: 09/18/23 Due: 09/18/24

Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06908733 Org: User:
Start: 03/31/25 End: 12/30/29 Due: 12/30/30

Anlotinib Hydrochloride Combined With Epirubicin and Ifosfamide for Soft Tissue Sarcoma Patients

Phase: N/A Priority: Normal
NCT ID: NCT03815474 Org: User:
Start: 05/20/19 End: 12/31/20 Due: 12/31/21

Zanubrutinib Combined With R-CHOP Regimen in the Treatment of Newly Diagnosed DLBCL With High-risk Factors

Phase: N/A Priority: Normal
NCT ID: NCT05887726 Org: User:
Start: 08/01/23 End: 08/01/25 Due: 08/01/26

Real-world Study of Inetetamab in HER2-positive Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06305702 Org: User:
Start: 07/01/22 End: 01/31/24 Due: 01/31/25

Combined Use of Apatinib Mesylate and Vinorelbine Versus Single Use of Vinorelbine in Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03932526 Org: User:
Start: 06/24/19 End: 06/26/23 Due: 06/26/24

Bevacizumab Therapy Untreated Unresectable Liver Metastases From Colorectal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01763450 Org: User:
Start: 09/30/12 End: 09/30/14 Due: 09/30/15

A Phase II Study of Irinotecan in 3 Line or More Therapy in Local Recurrence or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02030678 Org: User:
Start: 09/30/14 End: 12/31/20 Due: 12/31/21

Irinotecan for Advanced and Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03562390 Org: User:
Start: 04/01/17 End: 12/31/21 Due: 12/31/22

Clinical Study of Fulvestrant Combined With Chidamide in the Treatment of Hormone Receptor-positive Advanced Breast Cancer Resistant to CDK4/6 Inhibitors

Phase: N/A Priority: Normal
NCT ID: NCT05191914 Org: User:
Start: 02/07/22 End: 12/30/22 Due: 12/30/23

To Evaluate Thrombosis Risk in Chemotherapy Patients With Solid Tumors Who Receiving Thrombocytopenia Treatment

Phase: N/A Priority: Normal
NCT ID: NCT05688306 Org: User:
Start: 09/02/20 End: 05/16/22 Due: 05/16/23

Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT05132985 Org: User:
Start: 01/01/22 End: 01/01/28 Due: 01/01/29

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

Phase: N/A Priority: Normal
NCT ID: NCT05720559 Org: User:
Start: 03/01/23 End: 09/01/26 Due: 09/01/27

Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer/gastroesophageal Junction Adenocarcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06764251 Org: User:
Start: 12/30/24 End: 03/31/28 Due: 03/31/29

Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery

Phase: N/A Priority: Normal
NCT ID: NCT06109454 Org: User:
Start: 03/21/24 End: 10/31/28 Due: 10/31/29

Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations

Phase: N/A Priority: Normal
NCT ID: NCT06299371 Org: User:
Start: 04/15/24 End: 04/15/29 Due: 04/15/30